SIGNALAI·Jun 4, 2026, 4:00 AMSignal75Medium term

Early Detection of Alzheimer's Disease Using Explainable Machine Learning on Clinical Biomarkers: A Multi-Class Classification Study Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) Dataset

Source: arXiv cs.LG

Share
Early Detection of Alzheimer's Disease Using Explainable Machine Learning on Clinical Biomarkers: A Multi-Class Classification Study Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) Dataset

arXiv:2606.03995v1 Announce Type: new Abstract: Background: Alzheimer's disease (AD) affects over 55 million people worldwide. Accurate, interpretable detection of normal cognition (NC), mild cognitive impairment (MCI), and AD from routine clinical assessments remains a critical unmet need. Methods: An XGBoost classifier was developed for three-class detection using eight clinical features from the Alzheimer's Disease Neuroimaging Initiative (ADNI): MMSE, CDR Global, CDR Sum of Boxes (CDR-SB), MoCA, FAQ, age, sex, and education. Hyperparameters were optimised using Optuna (50 trials); class im

Why this matters
Why now

Advances in machine learning and data availability, specifically the ADNI dataset, are enabling more sophisticated early detection methods for neurological diseases.

Why it’s important

Early and accurate detection of Alzheimer's allows for timely intervention, potentially slowing disease progression and improving patient outcomes, while also reducing the societal and economic burden.

What changes

The ability to accurately classify cognitive states earlier using routine clinical data could transform diagnostic pathways and drug development for neurodegenerative diseases.

Winners
  • · AI in healthcare companies
  • · Pharmaceutical companies
  • · Patients with neurological conditions
  • · Clinical diagnostics sector
Losers
  • · Traditional diagnostic methods
  • · Late-stage pharmaceutical interventions
Second-order effects
Direct

Improved early diagnosis of Alzheimer's disease using explainable AI models.

Second

Accelerated development of targeted therapies and preventative measures as patient cohorts for trials become more precisely defined.

Third

Potential for AI-driven disease prediction to become a standard component of preventative healthcare, integrating into routine medical check-ups.

Editorial confidence: 90 / 100 · Structural impact: 55 / 100
Original report

This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.

Read at arXiv cs.LG
Tracked by The Continuum Brief · live intelligence network
Share
The Brief · Weekly Dispatch

Stay ahead of the systems reshaping markets.

By subscribing, you agree to receive updates from THE CONTINUUM BRIEF. You can unsubscribe at any time.